LYMPHOMAS

Victor A. Chow, MD, discusses the next steps for chimeric antigen receptor T-cell therapy in patients with B-cell lymphomas.

Polatuzumab vedotin, an antibody-drug conjugate that has demonstrated a 40% complete response rate in patients with relapsed/refractory diffuse large B-cell lymphoma, has been granted a priority review designation by the FDA in combination with bendamustine and rituximab for the treatment of these patients, according to Genentech, the manufacturer of the agent.

Brian T. Hill, MD, PhD, discusses the safety findings from the ZUMA-1 trial investigating axicabtagene ciloleucel (KTE-C19, axi-cel) in patients with diffuse large B-cell lymphoma.

Elizabeth L. Budde, MD, PhD, discusses the interim efficacy results form the phase I study of mosunetuzumab in patients with lymphomas.

Updated data from the JULIET trial, which were presented at the 2018 ASH Annual Meeting, underscore the impact of tisagenlecleucel for patients with diffuse large B-cell lymphoma, said Richard T. Maziarz, MD, the trial's lead investigator.

Umbralisib was granted a breakthrough therapy designation by the FDA for the treatment of adult patients with marginal zone lymphoma who have received 1 prior anti-CD20 regimen.

Brian T. Hill, MD, PhD, discusses data from a retrospective trial looking at the use of axicabtagene ciloleucel (axi-cel; Yescarta) in patients with diffuse large B-cell lymphoma.

Anas Younes, MD, discusses findings from a subset analysis from the PHOENIX trial in patients with DLBCL. He also highlights another trial investigating R-CHOP plus a PD-L1 inhibitor in this patient population.

Brian T. Hill, MD, PhD, discusses real-world findings with axi-cel in patients with DLBCL and how these findings can be used to inform practice.

The dose-adjusted EPOCH-R chemotherapy regimen induced either a complete or partial response in 87% of patients with aggressive B-cell lymphomas with an <em>MYC</em> rearrangement, a population that has had historically poor prognoses with rituximab plus R-CHOP.

Classical Hodgkin Lymphoma: Is There a Cure?

John P. Leonard, MD, discusses the primary results from the randomized, double-blind phase III AUGMENT trial investigating the combination lenalidomide (Revlimid) plus rituximab (Rituxan) in patients with recurrent indolent lymphomas.

During a <em>Targeted Oncology</em> live case-based peer perspectives presentation, Jonathon B. Cohen, MD, MS, recently discussed the treatment considerations and decisions he makes when treating patients with classical Hodgkin Lymphoma

Andre Goy, MD, discusses the data presented at the 2018 ASH Annual Meeting for combination lenalidomide plus rituximab, also known as the R² regimen, for the treatment of patients with relapsed/recurrent follicular lymphoma.<br /> &nbsp;

The combination of ibrutinib and durvalumab demonstrated a modest clinical benefit for patients with relapsed or refractory follicular lymphoma and germinal center B-cell diffuse large B-cell lymphoma, according to the results of a phase I/II trial.

Viola Poeschel, MD, discusses the results for the phase III FLYER trial in which the standard 6 cycles of R-CHOP were compared to a reduced 4 cycles of R-CHOP in patients with diffuse large B-cell lymphoma

Viola Poeschel, MD,&nbsp;discusses findings from the phase III FLYER trial and how they will impact the treatment landscape for younger patients with favorable-prognosis DLBCL.<br /> &nbsp;

According to findings from the&nbsp;phase IIb SADAL study, selinexor demonstrated deep and durable responses in patients with&nbsp;relapsed/refractory diffuse large B-cell lymphoma who are not candidates for autologous stem cell transplantation.

Victor A. Chow, MD, discusses findings of a retrospective study that looked at 55 patients with various B-cell lymphomas who progressed after treatment with CD19-specific CAR T cells.

The use of&nbsp;brentuximab vedotin in combination with chemotherapy has been recommended for approval by the&nbsp;European Medicines Agency&rsquo;s Committee for Medicinal Products for Human Use as a frontline treatment for&nbsp;adult patients with CD30+ stage IV Hodgkin lymphoma.